Albaghdady A,El-Asmar K,Moussad M,Abdelhay S M .2016 .and chyloperitoneum in a newborn]. Russ J Pediatr Surg, 6(1) : 95-9.
Wang B,Feng Y,Guo Y,Kan Q,Zou Y,Wu Y .2022 .Clinical features and outcomes of congenital chylothorax: a single tertiary medical center experience in China. J Cardiothorac Surg, 17 : 276.
Kucherov YI,Kholodnov NV,Adleiba SR,Belaya AL,Makarova LM,Ovsyannikova MA .2019 .Chyloperitoneum in newborns: etiology, pathogenesis, diagnostics. Russ J Pediatr Surg, 23(3) : 139-142.
Rudakova EA,Kovaleva OA,Openysheva AV,Koroleva MA .2015 .Results of treatment of chyloperitoneum in a newborn]. Permskiy meditsnskiy zhurnal, 32(6) : 78-83.
Saziye K,Gino G,Afksendiyos K. .2012 .Somatostatin treatment of persistent chyloperitoneum following abdominal aortic surgery. J Vasc Surg, 56(5) : 1409-12.
Ilaria A,Mariarosa C,Genny R,Giacomo C,Fabrizio C,Silvana G .2017 .The use of sirolimus in the treatment of giant cystic lymphangioma: Four case reports and update of medical therapy. Medicine (Baltimore), 96(51) : e8871.
Donyush EK,Kondrashova ZA,Polyaev YA,Garbuzov RV .2020 .Experience of using sirolimus in the treatment of children with vascular anomalies]. Russ J Pediatr Hematol Oncol, 7(3) : 22-31.
Kireeva NB,Pivikov VE,Novopoltsev EA,Tumakova NB,Plokharsky NA,BiryukovYP NA .2016 .Chylothorax and. newborns: 4 case report]. Russ J Pediatr Surg, 6(4) : 88-90.
Attar MA,Donn SM .2017 .Congenital chylothorax. Semin Fetal Neonatal Med, 22(4) : 234-9.
Antao B,Croaker D,Squire R .2003 .Successful management of congenital chyloperitoneum with fibrin glue. J Pediatr Surg, 38(11) : E54.
Mahajan P,Fernandes CJ,Margolin JF,Iacobas I. .2022 .Sirolimus efficacy in the treatment of critically ill infants with congenital primary chylous effusions. Pediatr Blood Cancer, 69 : e29510.
Karagol BS,Zenciroglu A,Gokce S,Kundak AA,Ipek MS .2010 .Therapeutic management of neonatal chylous ascites: Report of a case and review of the literature. Acta Paediatr, 99 : 1307-10.
Bhatia C,Pratap U .2001 .Octreotide therapy: a new horizon in treatment of iatrogenic chyloperitoneum. Arch Dis Child, 85 : 234-5.
Roehr CC,Jung A,Proquitté H,Blankenstein O,Hammer H,Lakhoo K .2006 .Somatostatin or octreotide as treatment options for chylothorax in young children: a systematic review. Intensive Care Med, 32 : 650-7.
Bellini C,Cabano R,De Angelis LC,Bellini T,Calevo MG,Gandullia P .2018 .Octreotide for congenital and acquired chylothorax in newborns: a systematic review. J Paediatr Child Health, 54(8) : 840-7.
Reck-Burneo CA,Parekh A,Velcek FT .2008 .Is octreotide a risk factor in necrotizing enterocolitis. J Pediatr Surg, 43 : 1209-1210.
Scottoni F,Fusaro F,Conforti A,Morini F .2015 .Pleurodesis with povidone-iodine for refractory chylothorax in newborns: Personal experience and literature review. J Pediatr Surg, 50 : 1722-5.
Parkhitko AA,Favorova OO,Khabibullin DI,Anisimov VN,Henske E.P.,Kinase E.P. .2014 .mTOR: Regulation and role in maintenance of cellular homeostasis, tumor development, and aging. Biokhimiya, 79(2) : 128-43.
Mizuno T,Fukuda T,Emoto C,Mobberley-Schuman PS,Hammill AM,Adams DM .2017 .Developmental pharmacokinetics of sirolimus: Implications for precision dosing in neonates and infants with complicated vascular anomalies. Pediatr Blood Cancer, 00 : e26470.